American Journal of Cancer Research
Overview
American Journal of Cancer Research is a scientific journal, published since 2011 in English. The journal's country of origin is United States and its primary focus area is oncology.
Details
Details
Abbr.
Am J Cancer Res
Start
2011
End
Continuing
Frequency
Quarterly
e-ISSN
2156-6976
Country
United States
Language
English
Specialty
Oncology
Recent Articles
1.
Ataie-Kachoie P, Pillai K, Badar S, Akhter J, Morris D
Am J Cancer Res
. 2025 Mar;
15(2):833-834.
PMID: 40084381
[This corrects the article on p. 2064 in vol. 8, PMID: 30416856.].
2.
Gharib F, Ammar M, Elhamshary A, Sheta M, Mansour W, Elkady A
Am J Cancer Res
. 2025 Mar;
15(2):643-651.
PMID: 40084380
Unfavorable T2 glottic squamous cell carcinoma with impaired vocal cord mobility and/or bulky disease has been a real treatment challenge with high local failure rates. The purpose of this study...
3.
Yang C, Chen W, Shia B, Wu S
Am J Cancer Res
. 2025 Mar;
15(2):618-630.
PMID: 40084379
Chronic obstructive pulmonary disease (COPD) patients face an increased risk of developing various malignancies due to shared risk factors and underlying systemic inflammation. N-acetylcysteine (NAC) has shown potential anticancer properties...
4.
Kuo Y, Chen Y, Tsai M, Lu S, Hu T, Hung C, et al.
Am J Cancer Res
. 2025 Mar;
15(2):811-823.
PMID: 40084378
Atezolizumab plus bevacizumab (Ate/Bev) and lenvatinib (Len) are first-line therapies for unresectable hepatocellular carcinoma (uHCC). However, Ate/Bev's high cost limits its common use in real-life practice, while Len is usually...
5.
Qi W, Zhang S
Am J Cancer Res
. 2025 Mar;
15(2):426-438.
PMID: 40084377
The current investigation sought to explore the effects and its possible mechanisms of Scavenger receptor class A member 5 (SCARA5) in model of colon cancer (CC). Patients diagnosed with CC...
6.
Jing Y, Liu C, Wang L, Liu X, Wang L
Am J Cancer Res
. 2025 Mar;
15(2):652-660.
PMID: 40084376
Objectives: This study aimed to explore the relationship between psychological resilience (PR) and symptom burden in postoperative brain glioma (BG) patients and to identify factors influencing this relationship. Methods: A...
7.
Weber R, Schulze K, Kenney N, Scheuermann B, Kunkel O, Ade C, et al.
Am J Cancer Res
. 2025 Mar;
15(2):487-500.
PMID: 40084375
Breast cancer patients' maximal O uptake (V̇Omax) values average 60-80% of age-predicted values which is often attributed to adjuvant therapy rather than risk factors, comorbidities, or the tumor and associated...
8.
Li X, Li L, Zhang L
Am J Cancer Res
. 2025 Mar;
15(2):470-486.
PMID: 40084374
Objective: To develop an individualized prediction model for myelosuppression risk in lung cancer patients undergoing platinum-based doublet chemotherapy and validate its predictive efficacy. Methods: A retrospective analysis was conducted on...
9.
Okoro J, Bulusu R, Frimpong E, Zhu X, Rogers S, Agyare E
Am J Cancer Res
. 2025 Mar;
15(2):684-704.
PMID: 40084373
Gemcitabine (Gem) is approved for use in pancreatic cancer chemotherapy. However, Gem undergoes rapid metabolism in the blood, producing an inactive metabolite. Due to this rapid metabolism, the effective dose...
10.
Lei Z, Chai H, Liu X, Jiang Y
Am J Cancer Res
. 2025 Mar;
15(2):517-532.
PMID: 40084372
Background: Hepatocellular carcinoma (HCC) is a prevalent malignancy worldwide, with portal vein tumor thrombosis (PVTT) worsening its prognosis and complicating management. The combination of transarterial chemoembolization (TACE) and the targeted...